Effects of nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study

Hellenic Journal of Cardiology

Volumn 46, Issue 3, 2005, Pages 199-207

  Patrianakos, Alexandros P ^a   Parthenakis, Fragiskos I ^a   Mavrakis, Hercules E ^a   Saatsaki, Maria ^a   Diakakis, Georgios F ^a   Chlouverakis, Gregorios I ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Beta blocker; Exercise test; Heart failure; Left ventricular diastolic function; Left ventricular ejection fraction

Indexed keywords

NEBIVOLOL; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; COMPARATIVE STUDY; DOPPLER ECHOCARDIOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; ETHANOLAMINES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 24644504908     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Packer M, Bristow MR, Cohn JN, et al: Effect of Carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
2. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study-II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
3. MERIT-HF Study Group: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
4. Poole-Wilson PA, Swedberg K, Cleland JG F, et al, for the COMET investigators: Comparison of Carvedilol and Metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
5. Cockroft JR, Chowenczyk PHJ, Brett SE, et al: Nebivolol vasodilates human forearm vasculature: evidence for L-argininy NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-1071.
6. Kalinowski L, Dobrucki L, Szczepanska-Konkel M, et al: Third-generation [beta]-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation 2003; 107: 2747-2752.
7. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
8. British Standards Institution (1994) Accuracy (trueness, precision) of measurement methods and results: general principles and definitions HMO London. BS ISO 5725 parts 1 and 2.
9. Massion PB, Feron O, Dessy C, Balligand JL: Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 2003 Sep 5; 93: 388-398.
10. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G: Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998 Oct; 32: 955-963.
11. Janssens S, Pokreisz P, Schoonjans L, et al: Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res. 2004 May 14; 94: 1256-1262.
12. Heger J, Godecke A, Flogel U, et al: Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res. 2002 Jan 11; 90: 93-99.
13. Hare JM, Givertz MM, Creager MA, Colucci WS: Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation. 1998; 97: 161-166.
14. Packer M, Coats A, Fowler M, et al, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 334: 1651-1658.
15. Dargie HJ, the CAPRICORN Investigators: Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
16. Kukin M, Kalman J, Charney R, et al: Prospective, randomized comparison of effect of long-term treatment with metoprolol or Carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999; 99: 2645-2651.
17. Metra M, Giubbini R, Nodari S, Boldi E, Modena M, Dei Cas L: Differential effects of b-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of Metoprolol versus Carvedilol. Circulation. 2000; 102: 546-551.
18. Bristow M, Gilbert E, Abraham W, et al, for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation: 1996; 94: 2807-2816.
19. Khattar R, Senior R, Soman P, Does R, Lahiri A: Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and Carvedilol. Am Heart J 2001; 142: 704-713.
20. Groenning B, Nilsson J, Sondergaard L, Fritz-Hansen T, Larsson H, Hildebrandt P: Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36: 2072-2080.
21. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, Paulus WJ: Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999 Jun 15; 99: 3009-3016.
22. Hare JM: Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol. 2003; 35: 719-729.
23. Andersson B, Caidahl K, di Lenarda A, et al: Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 673-682.
24. Andersson B, Stromblad SO, Lomsky M, Waagstein F: Heart rate dependency of cardiac performance in heart failure patients treated with Metoprolol. Eur Heart J 1999; 20: 575-583.
25. Quaife R, Gilbert E, Christian P, et al: Effects of Carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 1996: 78; 779-784.
26. Clements I, Miller W: Effect of Metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy. Am Heart J 2001; 141: 259-266.
27. Capomolla S, Febo O, Gnemmi M, et al: B-blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by Carvedilol. Am Heart J 2000; 139: 596-608.
28. Rousseau MF, Chapelle F, Van Eyll C, et al: Medium-term effects of beta-blockade on left ventricular mechanics: a double blind, placebo-controlled comparison of Nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996 Mar; 2: 15-23.
29. Kuecherer H F, Muhiudeen I A, Kusumoto F M, et al: Estimation of mean left atrial pressure from transesophageal pulsed Doppler echocardiography of pulmonary venous flow. Circulation 1990; 82: 1127-1139.
30. Gilbert EM, Anderson JL, Deitchman D, et al: Long-term b-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223-229.
31. Bristow MR, O'Connell JB, Gilbert EM, et al, for the Bucindolol Investigators: Dose response of chronic beta-blocker treatment in heart failure from idiopathic, dilated, or ischemic cardiomyopathy. Circulation 1994; 89: 1632-1642.
32. Australia/New Zealand Heart Failure Research Collaborative Group: Randomized, placebo-controlled trial of Carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
33. Metra M, Nardi M, Giubbini R, Dei Cas L: Effects of short-and long-term Carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678-1687.
34. Olsen SL, Gilbert EM, Renlund DG, et al: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995; 25: 1225-1231.
35. Gullestad L, Manhenkeb C, Aarslandb T, et al: Effect of Metoprolol CR_XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. Eur J Heart Fail 2001; 3: 463-468.
36. Brehm B, Wolf S, Corner S, Buck-Muller N, Risler T: Effect of Nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002; 4: 757-763.